ESAB Corp (ESAB) Stock Analysis

Verdict: AVOID

Debt-funded Eddyfi acquisition and asbestos litigation overhang weigh on earnings, leaving ESAB vulnerable despite 4.9% FCF yield.

Investment score: 37/100

Analysis as of

Is ESAB Corp stock worth reviewing? AI model thesis

The AI model sees ESAB Corp as an AVOID due to elevated balance sheet leverage (Net Debt/EBITDA 4.97x following the $1.49B Eddyfi acquisition), negative earnings surprise momentum (-5.3% in Q2 2026), and litigation risk surrounding historic asbestos claims.

7-factor investment score

ESAB Corp opportunities and risks

What speaks for ESAB

What speaks against ESAB

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
ESAB24.0x1.3x14.0x35.7%5.7%4.9%
JBTM29.7x1.5x13.4x35.6%4.9%5.4%
MIDDn/a1.4xn/a38.0%-13.2%9.8%
CR34.0x4.4x21.7x41.7%13.0%2.5%
FELE27.5x1.9x16.3x35.5%7.1%5.1%
ALH23.5x2.4x13.7x37.7%10.1%6.0%
Peer median27.5x1.9x13.7x37.7%7.1%5.4%

Frequently asked questions about ESAB Corp (ESAB)

Is ESAB stock a good investment?

The cached TradeMates AI model rates ESAB Corp as AVOID with an investment score of 37/100. The AI model sees ESAB Corp as an AVOID due to elevated balance sheet leverage (Net Debt/EBITDA 4.97x following the $1.49B Eddyfi acquisition), negative earnings surprise momentum (-5.3% in Q2 2026), and litigation risk surrounding historic asbestos claims. This is algorithmic model output, not personal investment advice.

Is ESAB stock a buy?

The TradeMates model verdict for ESAB is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.